Metamizole induced liver injury: Direct health care professional communication (DHPC)

European Medicines Agency (EMA) released a direct health care professional letter (DHPC) pertaining to the risk of drug-induced liver injury (DILI) by metamizole. We encourage all health care professionals to be aware of this new safety alert and to disseminate this significant information to the relevant stakeholders for a better patient safety. Metamizole (also known

Fingolimod induced liver injury : DHPC from Novartis

A direct health care professional communication (DHPC) released by Novartis in liaison with European medicines agency (EMA) and some of national competent authorities in Europe to disseminate important safety information pertaining to drug (fingolimod) induced liver injury to alert healthcare professionals for a careful benefit -risk analysis and early implementation of risk minimization measures for

Notice: Undefined variable: shuttle_blog_postswitch in /var/www/wp-content/themes/shuttle-pro/admin/main/options/05.blog.php on line 634
class="blog-article post-1971 post type-post status-publish format-standard has-post-thumbnail hentry category-drug-safety-alert category-drug-safety-updates category-pharmacovigilance tag-angiotensin-ii-receptor-blocker tag-fimasartan tag-hsa tag-liver-injury tag-singapore-health-authority format-media">

HSA Drug Safety Alert: Liver Injury associated with Fimasartan use

The Health Science Authority (HSA) of Singapore government released a new drug safety alert for the fimasartan. Fimasartan is a non-peptide angiotensin II receptor blocker (ARB) used for the treatment of hypertension and heart failure. On 09-Sep-2010, fimasartan was initially approved in South Korea and is marketed under the brand name Kanarb by Boryung Pharmaceuticals.  In

error: Content is protected !!